Connect with us

News

Superfood spirulina harnessed as biomanufacturing engine

Published

on

A common food source has been converted into a biomanufacturing platform that enables mass production of biologic drugs for common diseases that currently lack effective treatments.

Researchers at Lumen Bioscience have pioneered genetic engineering methods to highly express bioactive proteins in spirulina using large-scale cultivation and processing methods appropriate for biopharmaceutical manufacturing.

A report on their findings also details favourable preclinical and early-stage clinical testing of these manufactured, orally delivered neutralising antibodies against campylobacter, a major cause of infant mortality in the developing world and a growing antibiotic resistance threat.

The product, LMN-101, is now proceeding through Phase 2 clinical trials, and BARDA’s CARB-X programme is funding the development of a second-generation version of this product.

Jim Roberts, lead author and co-founder and chief scientific officer of Lumen Bioscience, says: “Genetic engineering has transformed the manufacturing of biological products over the past 50 years, yet plant-based biopharmaceutical production has remained an elusive challenge.

“Spirulina-based biomanufacturing combines the safety of food-based biotechnology with genetic engineering methods to produce biopharmaceuticals that may address medical needs that current drug-development tools have failed to solve.”

Spirulina, a photosynthetic cyanobacterium, is a highly nutritious food and the only microorganism commercially farmed worldwide as a food.

Previous attempts to convert this safe, scalable food source into a biomanufacturing platform have proven futile. In the new paper, Lumen researchers detail methods for the constitutive and stable expression of protein therapeutics in spirulina, with productivities and potencies tens to hundreds of fold higher than achievable in other food-based platforms.

These advances in scalability and potency make orally delivered biologics commercially feasible for the first time.

Roberts says: “Delivering therapeutic amounts of protein biologics to the intestine presents an enormous challenge, and for this reason targets in the GI tract have long been considered almost undruggable.

“The spirulina platform elegantly addresses this challenge. It can be used to produce and deliver the enormous quantities of ingestible biotherapeutics that will be needed to both prevent and treat gastrointestinal diseases.

“Preventing and treating diarrheal disease, the example reported in today’s paper, offers an excellent case study: these highly prevalent diseases have devastating impacts in the developing world, but traditional drug-making tools have failed to generate a solution despite decades of heavy investment. The approach described in today’s publication offers new hope to the individuals exposed to these diseases.”

Lumen Bioscience discovers, develops, and manufactures biologic drug candidates for highly prevalent diseases—many of which currently lack any effective treatments.

The company’s drug development and manufacturing platform offers the potential to transform the biologics industry through increased speed, mass-market scale, and exponentially lower costs than current approaches.

Continue Reading
1 Comment

1 Comment

  1. Pingback: CellRev rebrands as it prepares for market launch | Health Tech World

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending stories

Copyright © 2022 Aspect Publishing Ltd.

[vgoAlias]
[vgoAlias]
[id^="_form"]
[id^="_form"]
[id$="_submit"]
[id$="_submit"]
[^;]
[^;]
[(d+)]
[(d+)]
[elem.name]
[elem.name]
[+_a-z0-9-'&=]
[+_a-z0-9-'&=]
[+_a-z0-9-']
[+_a-z0-9-']
[a-z0-9-]
[a-z0-9-]
[a-z]
[a-z]
[el.name]
[el.name]